Arthneeti
All Q3 FY25 results →
ZW

Zydus Wellness Ltd

Q3 FY25Food Products

Zydus Wellness Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹491
Market cap₹16.9K Cr
P/E76.2
Updated23 Aug 2026
Read4 min read

The short version

The company expects to sustain double-digit top-line revenue growth in FY '26 and beyond. Management expects to sustain double-digit top-line growth in FY '26 and beyond.

From Zydus Wellness Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company expects to sustain double-digit top-line revenue growth in FY '26 and beyond.
  • Personal Care segment has shown consistent double-digit growth over the last 6-7 quarters, driven by category expansion and market leadership.
  • Digital channel (e-commerce) now contributes about 10%-11% of revenue and growing faster than other segments.
  • Food & Nutrition segment growth is improving, although some sizable brands like Complan show lower growth; initiatives underway to improve this.
  • New product launches like protein chips and cookies under Max Protein are positively building momentum.
  • Management remains focused on driving growth ahead of the industry, targeting better performance and improving profitability.

2 more points from Zydus Wellness Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Zydus Wellness Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The transcript and report excerpts do not explicitly mention any specific current or future capital expenditure (capex) or strategic capital investments by Zydus Wellness Limited. However, some relevant points include: - Focus on category development and brand extension (e.g., extending Nutralite into cheese, mayonnaise; Sugar Free into chocolates and cookies) which may imply marketing or product development investments. - Acquisitions have been described as "bolt-ons" to fill portfolio gaps, with Ritebite acquisition expected to be EPS accretive by FY '26. - Investments in digital and AI capabilities for improved consumer engagement and sales force efficiency.

2 more points from Zydus Wellness Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Food Products

Ranked on what management guided this quarter

Guidance-ranked
1Nurture Well Industries
Rev 1Mar 1
2Hoac Foods
Rev 1Mar 1
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Zydus Wellness Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript for Zydus Wellness Limited’s Q3 FY2025 earnings call does not provide specific details about the current or expected order book or pending orders. However, relevant insights related to business performance and outlook include: - Strong focus on double-digit growth in revenue and EBITDA. - Confidence in sustaining growth momentum with new product launches and expansion in digital channels. - Anticipation of revival in demand, especially in urban areas, supported by government measures in Budget 2025.

2 more points from Zydus Wellness Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Zydus Wellness Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.5K Cr, net profit ₹162 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Zydus Wellness Ltd's management said in earlier quarters

Others in Food Products this season

  • Venky's (India) (Q3 FY25)

    881.61 Crore (no year-on-year change stated). Key concall takeaways from Venkys (India) Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

  • Prataap Snacks Ltd (Q3 FY25)

    Revenue/Sales for Q3 FY25: INR 4,426.9 million, a 9.0% increase YoY (Q3 FY24: INR 4,062.4 million). Key concall takeaways from Prataap Snacks Ltd's Q3 FY25…

  • Sharat Industrie (Q3 FY25)

    Revenue: ₹96.45 Crores, up 58.8% Year-on-Year (YoY) . Key concall takeaways from Sharat Industries Ltd's Q3 FY25 earnings call — and how it ranks against…

  • Apex Frozen Food (Q3 FY25)

    Capacity utilization currently at ~35%, with potential to improve if supply stabilizes. Key concall takeaways from Apex Frozen Foods Ltd's Q3 FY25 earnings…

Compare:vs Nestle Indiavs Britannia Inds.vs Hatsun Agro

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Zydus Wellness Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Zydus Wellness Ltd Q3 FY25 results?

The company expects to sustain double-digit top-line revenue growth in FY '26 and beyond. Management expects to sustain double-digit top-line growth in FY '26 and beyond.

What is Zydus Wellness Ltd share price analysis?

Zydus Wellness Ltd currently shows a neutral. The stock trades at a P/E of 76.2 with a market cap of ₹16,875 Cr. Investors should review the full earnings analysis for detailed insights.

Is Zydus Wellness Ltd planning capital expenditure?

The transcript and report excerpts do not explicitly mention any specific current or future capital expenditure (capex) or strategic capital investments by Zydus Wellness Limited.

Keep Zydus Wellness Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.